Vosoritide (VOXZOGO): Uses, Evidence, Side Effects

Key takeaways

• Vosoritide is approved to increase linear growth in children with achondroplasia who still have open growth plates.
• It works by binding a natriuretic peptide receptor that counters the overactive signaling driving achondroplasia's growth restriction.
• The approval is an accelerated approval tied to growth velocity, with continued approval contingent on confirmatory trial results.
• Eighteen trials have been registered for vosoritide, including active studies in achondroplasia and hypochondroplasia.
• Reported adverse event submissions for vosoritide are dominated by medication handling errors rather than a specific safety signal.

What vosoritide is

Vosoritide is a synthetic analog of C-type natriuretic peptide, marketed as VOXZOGO. In achondroplasia, a gain-of-function mutation in the FGFR3 receptor overactivates a signaling cascade (ERK1/2 within the MAPK pathway) that suppresses bone growth. Vosoritide binds natriuretic peptide receptor-B and works against that downstream FGFR3 signaling, which is thought to support more typical bone growth.

What vosoritide is approved for

VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia who still have open epiphyses (growth plates). It is available in three labeled strengths: VOXZOGO 0.4mg, VOXZOGO 0.56mg, and VOXZOGO 1.2mg. This indication carries accelerated approval based on improvement in annualized growth velocity, meaning continued approval may depend on confirmatory trials verifying clinical benefit. The label does not carry a boxed warning.

What the evidence shows

Vosoritide has 18 registered trials spanning related skeletal growth conditions. A Phase 3 study is evaluating vosoritide in children with hypochondroplasia and is active but no longer recruiting. Separately, a Phase 2 extension study (under the compound's earlier designation, BMN 111) has been following long-term safety and efficacy in children with achondroplasia and is also active, not recruiting.

Reported side effects

Available adverse event reports tied to vosoritide are limited and reflect report counts, not confirmed incidence or causation. The entries on record involve medication handling issues: dose calculation error, product preparation error, and product prescribing error, each with a single report. This pattern points more toward administration and preparation processes than toward a specific drug-related adverse effect.